NO803726L - Fremgangsmaate for diagnose av cystisk fibrose - Google Patents

Fremgangsmaate for diagnose av cystisk fibrose

Info

Publication number: NO803726L
Authority: NO; Norway
Prior art keywords: enzyme; examination; cells; determination; activity
Prior art date: 1979-04-16

Application number

NO80803726A

Other languages

English (en)

Norwegian (no)

Inventor

Burton L Shapiro

Original Assignee

Univ Minnesota

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1979-04-16

Filing date

1980-12-10

Publication date

1980-12-10

1980-12-10 Application filed by Univ Minnesota filed Critical Univ Minnesota

1980-12-10 Publication of NO803726L publication Critical patent/NO803726L/no

Links

238000000034 method Methods 0.000 title claims description 25
238000003745 diagnosis Methods 0.000 title claims description 8
206010016654 Fibrosis Diseases 0.000 title 1
210000004027 cell Anatomy 0.000 claims description 65
201000003883 Cystic fibrosis Diseases 0.000 claims description 48
102000004190 Enzymes Human genes 0.000 claims description 48
108090000790 Enzymes Proteins 0.000 claims description 48
230000000694 effects Effects 0.000 claims description 35
239000000969 carrier Substances 0.000 claims description 31
102000006746 NADH Dehydrogenase Human genes 0.000 claims description 18
108010086428 NADH Dehydrogenase Proteins 0.000 claims description 18
210000003470 mitochondria Anatomy 0.000 claims description 16
201000010099 disease Diseases 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
230000002438 mitochondrial effect Effects 0.000 claims description 12
230000005764 inhibitory process Effects 0.000 claims description 10
238000011835 investigation Methods 0.000 claims description 10
210000004698 lymphocyte Anatomy 0.000 claims description 10
239000000758 substrate Substances 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 9
238000012360 testing method Methods 0.000 claims description 9
238000004134 energy conservation Methods 0.000 claims description 7
230000005787 mitochondrial ATP synthesis coupled electron transport Effects 0.000 claims description 7
230000036284 oxygen consumption Effects 0.000 claims description 7
208000024891 symptom Diseases 0.000 claims description 5
210000004369 blood Anatomy 0.000 claims description 4
239000008280 blood Substances 0.000 claims description 4
239000000872 buffer Substances 0.000 claims description 4
239000000284 extract Substances 0.000 claims description 4
238000010982 kinetic investigation Methods 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 3
239000003708 ampul Substances 0.000 claims description 2
230000003185 calcium uptake Effects 0.000 claims description 2
238000002955 isolation Methods 0.000 claims 1
229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 15
210000002950 fibroblast Anatomy 0.000 description 11
BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 11
239000011575 calcium Substances 0.000 description 10
229940080817 rotenone Drugs 0.000 description 9
JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 description 9
238000002474 experimental method Methods 0.000 description 7
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
239000000370 acceptor Substances 0.000 description 6
229910052791 calcium Inorganic materials 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
239000006285 cell suspension Substances 0.000 description 4
239000003112 inhibitor Substances 0.000 description 4
230000003647 oxidation Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
239000008057 potassium phosphate buffer Substances 0.000 description 4
210000001626 skin fibroblast Anatomy 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
239000012981 Hank's balanced salt solution Substances 0.000 description 3
BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
230000005856 abnormality Effects 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003834 intracellular effect Effects 0.000 description 3
229950006238 nadide Drugs 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
208000028782 Hereditary disease Diseases 0.000 description 2
108010020056 Hydrogenase Proteins 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
208000024556 Mendelian disease Diseases 0.000 description 2
XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 2
230000008859 change Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
210000002907 exocrine cell Anatomy 0.000 description 2
210000003499 exocrine gland Anatomy 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
206010052656 Cystic fibrosis carrier Diseases 0.000 description 1
102000018832 Cytochromes Human genes 0.000 description 1
108010052832 Cytochromes Proteins 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
229930182816 L-glutamine Natural products 0.000 description 1
XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
229940123669 Mitochondrial electron transport inhibitor Drugs 0.000 description 1
102000002023 NADH:ubiquinone oxidoreductases Human genes 0.000 description 1
108050009313 NADH:ubiquinone oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
208000035467 Pancreatic insufficiency Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010063493 Premature ageing Diseases 0.000 description 1
208000032038 Premature aging Diseases 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
AHLYXGYSBJNLAA-UHFFFAOYSA-N [K].N#C[Fe](C#N)C#N Chemical compound [K].N#C[Fe](C#N)C#N AHLYXGYSBJNLAA-UHFFFAOYSA-N 0.000 description 1
TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
235000017471 coenzyme Q10 Nutrition 0.000 description 1
239000000470 constituent Substances 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007547 defect Effects 0.000 description 1
229940080861 demerol Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000008151 electrolyte solution Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
230000004941 influx Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
PANJMBIFGCKWBY-UHFFFAOYSA-N iron tricyanide Chemical compound N#C[Fe](C#N)C#N PANJMBIFGCKWBY-UHFFFAOYSA-N 0.000 description 1
XYZXOFUXTBSQQI-UHFFFAOYSA-N iron(3+);tricyanide Chemical group [Fe+3].N#[C-].N#[C-].N#[C-] XYZXOFUXTBSQQI-UHFFFAOYSA-N 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
-1 oxidized form) Chemical compound 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000002028 premature Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
150000004053 quinones Chemical class 0.000 description 1
230000009758 senescence Effects 0.000 description 1
230000009919 sequestration Effects 0.000 description 1
239000002356 single layer Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000003774 sulfhydryl reagent Substances 0.000 description 1
210000004243 sweat Anatomy 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
150000003669 ubiquinones Chemical class 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Analytical Chemistry (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Physiology (AREA)
Food Science & Technology (AREA)
Tropical Medicine & Parasitology (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Exchange Systems With Centralized Control (AREA)
Analysing Materials By The Use Of Radiation (AREA)

NO80803726A 1979-04-16 1980-12-10 Fremgangsmaate for diagnose av cystisk fibrose NO803726L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/030,179 US4273869A (en)	1979-04-16	1979-04-16	Cystic fibrosis detection method

Publications (1)

Publication Number	Publication Date
NO803726L true NO803726L (no)	1980-12-10

Family

ID=21852910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO80803726A NO803726L (no)	1979-04-16	1980-12-10	Fremgangsmaate for diagnose av cystisk fibrose

Country Status (9)

Country	Link
US (1)	US4273869A (da)
EP (2)	EP0018202A1 (da)
CA (1)	CA1116501A (da)
DK (1)	DK458880A (da)
FR (1)	FR2454623A1 (da)
NO (1)	NO803726L (da)
NZ (1)	NZ193342A (da)
WO (1)	WO1980002294A1 (da)
ZA (1)	ZA802276B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5036861A (en) *	1990-01-11	1991-08-06	Sembrowich Walter L	Method and apparatus for non-invasively monitoring plasma glucose levels
US6183948B1 (en)	1998-04-15	2001-02-06	Johns Hopkins University	Methods to identify compounds affecting mitochondria
GB0209812D0 (en) *	2002-04-30	2002-06-05	Renovo Ltd	Genetic testing
ITMI20021148A1 (it) *	2002-05-28	2003-11-28	Univ Bologna	Metodo per la determinazione della funzionalita' mitocondriale in cellule isolate e relativo kit
WO2020124152A1 (en) *	2018-12-19	2020-06-25	Monash University	Assay for screening drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3899298A (en) *	1972-04-11	1975-08-12	Squibb & Sons Inc	Method and apparatus for angiotensin i determination
US3867258A (en) *	1973-11-08	1975-02-18	American Cyanamid Co	Lactate dehydrogenase test material
AT339505B (de) *	1974-03-14	1977-10-25	Boehringer Mannheim Gmbh	Enzymatisches analysenverfahren
US4042462A (en) *	1975-12-24	1977-08-16	Monsanto Company	Creatine phosphokinase determination method

1979
- 1979-04-16 US US06/030,179 patent/US4273869A/en not_active Expired - Lifetime
1980
- 1980-04-02 NZ NZ193342A patent/NZ193342A/xx unknown
- 1980-04-10 WO PCT/US1980/000370 patent/WO1980002294A1/en not_active Ceased
- 1980-04-14 EP EP80301221A patent/EP0018202A1/en not_active Ceased
- 1980-04-15 FR FR8008384A patent/FR2454623A1/fr not_active Withdrawn
- 1980-04-16 ZA ZA00802276A patent/ZA802276B/xx unknown
- 1980-04-16 CA CA000350006A patent/CA1116501A/en not_active Expired
- 1980-10-29 DK DK458880A patent/DK458880A/da not_active Application Discontinuation
- 1980-11-04 EP EP80900993A patent/EP0027143A1/en not_active Withdrawn
- 1980-12-10 NO NO80803726A patent/NO803726L/no unknown

Also Published As

Publication number	Publication date
NZ193342A (en)	1982-09-14
CA1116501A (en)	1982-01-19
DK458880A (da)	1980-10-30
FR2454623A1 (fr)	1980-11-14
US4273869A (en)	1981-06-16
EP0018202A1 (en)	1980-10-29
EP0027143A1 (en)	1981-04-22
ZA802276B (en)	1981-04-29
WO1980002294A1 (en)	1980-10-30

Publication	Publication Date	Title
Mahfouz et al.	2009	Evaluation of chemiluminescence and flow cytometry as tools in assessing production of hydrogen peroxide and superoxide anion in human spermatozoa
Ruiz-Pesini et al.	2000	Seminal quality correlates with mitochondrial functionality
Agarwal et al.	2016	MiOXSYS: a novel method of measuring oxidation reduction potential in semen and seminal plasma
Ahmad et al.	2017	Ascorbic acid reduces redox potential in human spermatozoa subjected to heat‐induced oxidative stress
Saleh et al.	2002	Leukocytospermia is associated with increased reactive oxygen species production by human spermatozoa
Pasqualotto et al.	2008	Semen quality and oxidative stress scores in fertile and infertile patients with varicocele
Massaro et al.	2012	Biomarkers of brain injury in neonatal encephalopathy treated with hypothermia
Trisini et al.	2004	Relationship between human semen parameters and deoxyribonucleic acid damage assessed by the neutral comet assay
Yeşilli et al.	2005	Effect of varicocelectomy on sperm creatine kinase, HspA2 chaperone protein (creatine kinase-M type), LDH, LDH-X, and lipid peroxidation product levels in infertile men with varicocele
Allamaneni et al.	2005	Characterization of oxidative stress status by evaluation of reactive oxygen species levels in whole semen and isolated spermatozoa
Moss et al.	1998	Alcohol consumption and the 5-year incidence of age-related maculopathy: the Beaver Dam eye study
Tu et al.	2010	Associations of a non-synonymous variant in SLC2A9 with gouty arthritis and uric acid levels in Han Chinese subjects and Solomon Islanders
Li et al.	2022	Habitual coffee consumption increases risk of primary open-angle glaucoma: a mendelian randomization study
ZALATA et al.	1998	The correlates and alleged biochemical background of the resazurin reduction test in semen
Gosálvez et al.	2017	Multi-centre assessment of nitroblue tetrazolium reactivity in human semen as a potential marker of oxidative stress
WO2022008802A1 (en)	2022-01-13	Method for determining amounts of nad metabolites from sample and methods and uses related thereto
Favre et al.	2008	Oxidative stress and chronological aging in glycogen-phosphorylase-deleted yeast
Misro et al.	2004	Use of hydrogen peroxide to assess the sperm susceptibility to oxidative stress in subjects presenting a normal semen profile
Guthrie	1972	Mass screening for genetic disease
Hayward et al.	2022	Real-time analysis of mitochondrial electron transport chain function in Toxoplasma gondii parasites using a seahorse XFe96 extracellular flux analyzer
Ferramosca et al.	2015	Varicocele negatively affects sperm mitochondrial respiration
Coats et al.	2002	Early increases in blood lactate following injury
Bennett et al.	2016	Potentially diagnostic electron paramagnetic resonance spectra elucidate the underlying mechanism of mitochondrial dysfunction in the deoxyguanosine kinase deficient rat model of a genetic mitochondrial DNA depletion syndrome
NO803726L (no)	1980-12-10	Fremgangsmaate for diagnose av cystisk fibrose
Hetyey et al.	2007	Plasma antioxidant capacity in dogs with naturally occurring heart diseases